Beta in finance measures how much an asset’s price moves relative to a benchmark index such as the S&P 500. A beta of 1.0 means the stock tracks the market. Above 1.0 signals amplified swings, below 1.0 signals muted ones, and a negative reading means the asset tends to move in the opposite direction of the market.
That definition is the easy part. The harder question is where the number actually comes from. Two platforms can publish wildly different betas for the same ticker on the same day because they used different lookback windows, different return frequencies, and different benchmarks. Anyone relying on a single published figure without knowing those inputs is working with a number they cannot defend.
This guide covers what beta actually measures, how it is calculated, and the ten platforms most widely used to pull, compute, or model it — with current pricing, honest trade-offs, and guidance on which tier is worth paying for.
What Beta Actually Measures
Beta comes out of modern portfolio theory, where it quantifies systematic risk. Systematic risk affects the entire market and cannot be diversified away, unlike company-specific risk that disappears across a broad enough basket of holdings. That distinction is what makes beta central to the Capital Asset Pricing Model, which ties expected return directly to a security’s beta.
Mathematically, beta is the covariance between an asset’s returns and the market’s returns, divided by the variance of the market’s returns. In practice that reduces to the slope of a regression line fitted through paired return observations. Most providers run five years of monthly returns against a broad index, though weekly and daily variants are common.
The interpretation is proportional rather than predictive. A stock with a beta of 1.4 has historically moved about 40 percent more than the index in both directions. It does not promise that relationship will hold next quarter, which is why any serious workflow pairs beta with R-squared to judge how much of the stock’s movement the benchmark actually explains.
Why the Same Stock Shows Different Betas
Three inputs drive nearly all the variation between providers. The first is the estimation window — a two-year beta and a five-year beta on the same ticker can differ by 0.3 or more when the company has changed materially. The second is return frequency, since daily returns pick up microstructure noise that monthly returns smooth out.
The third is benchmark selection. A US-listed stock measured against the S&P 500 will not produce the same beta as the same stock measured against a global index or a sector-specific one. Some providers also apply Blume adjustment, which shrinks raw beta toward 1.0 on the assumption that betas mean-revert over time.
None of these approaches is wrong. The mistake is comparing a Blume-adjusted five-year monthly beta from one source against a raw two-year weekly beta from another and treating the gap as meaningful. Consistency of method matters more than which method gets picked, particularly when the output feeds a cost of equity calculation or a discounted cash flow model.
The Top 10 Tools for Beta Analysis
The platforms below span free spreadsheet add-ons to institutional terminals. They are ordered from most accessible to most expensive, since budget is usually the binding constraint rather than capability.
1. Wisesheets — Best for Building Beta Into Spreadsheets
Wisesheets is an add-on for Microsoft Excel and Google Sheets that pulls financial statements, key metrics, and historical price data directly into cells through simple functions like WISE and WISEPRICE. For beta work specifically, that means pulling multi-year price series for a ticker and its benchmark into two columns and running SLOPE or LINEST across them.
Annual pricing runs about $60 for Pro, $120 for Elite, and $900 for Enterprise, which works out to roughly $5 per month at the entry tier. The Elite plan adds a screener that returns company lists with beta among the returned fields, useful when filtering a universe before deeper work. There is no permanent free tier.
Pros: extremely cheap, works inside the spreadsheet where models already live, full control over lookback window and frequency, pre-built templates including DCF models. Cons: no standalone interface, requires comfort with formulas, and data refresh depends on spreadsheet request quotas.
2. Simply Wall St — Best for Visual Risk Screening
Simply Wall St takes a deliberately visual approach, compressing a company’s value, growth, performance, health, and dividend profile into a single snowflake graphic. Beta and share price volatility appear inside the risk and performance sections of each company report, presented against industry and market averages rather than as a raw number.
Pricing sits at roughly $10.95 per month for Premium and $21.50 per month for Unlimited, with a free tier limited to one portfolio holding ten positions. Premium raises that to three portfolios of thirty holdings each; Unlimited allows five portfolios with unlimited holdings, ten screeners, and PDF and CSV exports of the underlying report data.
Pros: excellent global coverage beyond US markets, genuinely fast to read, cheapest credible paid tier in the category. Cons: minimal control over how metrics are calculated, no custom regression, and the middle Premium tier offers thin value relative to Unlimited.
3. Finbox — Best for Valuation Modelling on a Budget
Finbox is built around pre-configured valuation models — discounted cash flow, comparable company analysis, and multiples-based approaches — where beta feeds directly into the discount rate. That makes it one of the few affordable platforms where the beta figure has an immediate downstream use rather than sitting as an isolated data point.
The Starter plan runs about $10 per month, with the Professional tier at roughly $66 per month adding international coverage across Asian and emerging markets. That jump is steep, and investors who need non-US data should price-check alternatives before committing.
Pros: valuation models are the strongest in this price band, clean data presentation, low entry cost. Cons: charting is weak compared to peers, and global coverage sits behind a tier that costs six times the entry plan.
4. Portfolio Visualizer — Best for Portfolio-Level Beta and Factor Analysis
Portfolio Visualizer is the strongest option for measuring beta at the portfolio level rather than the security level. Its factor regression tools decompose returns against market, size, value, momentum, and quality factors, producing loadings that show precisely where portfolio risk originates. Backtesting, Monte Carlo simulation, and efficient frontier optimisation sit alongside it.
The free tier is unusually capable, handling portfolios up to roughly fifteen assets with limited history. Paid plans run about $30 per month for Basic and $55 per month for Pro, both billed annually at approximately $360 and $660, raising the asset limit to 150 and unlocking saving, importing, and export to Excel, CSV, and PDF. Pro adds clearance for commercial use.
Pros: factor analysis is genuinely institutional in quality, free tier does real work, transparent methodology. Cons: monthly data only, backtests reach back only as far as the newest fund in the mix, and portfolios must be entered manually with no brokerage sync.
5. Stock Rover — Best for Fundamental Screening With Correlation Tools
Stock Rover pairs a deep fundamental screener with portfolio analytics that include correlation analysis, Monte Carlo simulation, and dividend forecasting. Beta is screenable alongside hundreds of other metrics, and the correlation tool surfaces holdings that move together — often more actionable than beta alone when the goal is genuine diversification.
The platform restructured its plans following a major release, and current retail pricing runs $34 per month or $348 per year for Premium, $70 per month or $588 per year for Premium Plus, $99 per month or $948 per year for Ultimate, and $199 per month or $1,788 per year for Ultimate Pro. Metric depth scales by tier, from roughly 400 screenable fields at Premium to more than 800 at the top tiers, with up to twenty years of financial history. A permanent free plan exists but excludes the screener.
Pros: connects to more than a thousand brokerages, correlation and Monte Carlo tools that competitors charge far more for, deep historical fundamentals. Cons: data is delayed roughly fifteen to twenty minutes, there is no mobile app, and recent price increases have pushed it well above its former budget positioning.
6. Morningstar Investor — Best for Analyst-Backed Risk Context
Morningstar Investor supplies beta alongside standard deviation, R-squared, alpha, and the Sharpe ratio inside its risk statistics panel, calculated over three, five, and ten-year windows. The Portfolio X-Ray tool aggregates those figures to portfolio level and flags concentration by sector, region, and style box.
Pricing is $249 per year, or $34.95 billed monthly, with first-year promotional pricing frequently available near $199 and a seven-day free trial. The subscription also carries Morningstar’s fair value estimates, economic moat ratings, and Medalist Ratings for funds and ETFs, which is where much of the value sits for long-term holders.
Pros: multi-window risk statistics presented consistently, best-in-class fund and ETF research, strong value at the annual rate. Cons: no real-time data, charting is basic, and monthly billing costs roughly 40 percent more than annual over a year.
7. TradingView — Best for Charting Beta Against Price Action
TradingView is primarily a charting platform, but its Pine Script environment allows custom beta and rolling-beta indicators plotted directly beneath a price chart. That visual approach makes regime changes obvious in a way a static number never does — a stock whose beta drifted from 0.8 to 1.6 over eighteen months shows that shift as a visible slope.
The free Basic plan covers single-chart analysis with ads. Paid tiers have been repriced upward and currently sit near $14.95 per month for Essential, $29.95 for Plus, $59.95 for Premium, and $239.95 for Ultimate, with annual billing cutting roughly 13 to 17 percent off each. Exchange data fees stack on top, and professional-status users face dramatically higher feed costs.
Pros: unmatched charting, scriptable custom indicators, huge community library of published scripts. Cons: fundamental data is shallow, real exchange data fees can exceed the subscription itself, and pricing has climbed repeatedly.
8. Koyfin — Best Bloomberg Alternative for Serious Individuals
Koyfin is the closest thing to terminal-grade analytics at a retail price. It covers global equities, ETFs, commodities, bonds, and macro indicators, with dashboards that place beta beside valuation multiples, forward estimates, and risk metrics in a single view. Custom formulas let users define their own derived metrics.
The free plan is substantial, covering global screening, two years of financials, advanced charting, and macro dashboards. Plus runs $39 per month, Premium $79 per month, Advisor Core $209 per month, and Advisor Pro $299 per month, with annual billing available. The Premium tier is where mutual fund data, unlimited custom formulas, and model portfolio tools appear.
Pros: genuinely deep data for the price, strong dashboard customisation, ten years of financials and forward estimates at Plus. Cons: learning curve is real, portfolio risk analytics require the higher tiers, and advisor plans jump sharply in price.
9. YCharts — Best for Advisors Producing Client Reports
YCharts sits between retail platforms and full institutional systems, targeting registered investment advisors who need defensible risk statistics inside client-facing documents. Its proposal builder and report generator pull beta, drawdown, and correlation figures into branded PDFs, which is the actual product for most subscribers.
Pricing starts around $300 per month per user billed annually, roughly $3,600, with a professional tier near $500 per month or $6,000 annually and custom enterprise terms above that. There is a seven-day trial but no permanent free tier, and contracts are annual with no monthly option.
Pros: coverage spanning tens of thousands of equities and funds plus hundreds of thousands of economic indicators, high-touch support, client deliverables that look professional. Cons: pricing is opaque until sales contact, annual commitment only, and the cost is impossible to justify for individual investors.
10. Bloomberg Terminal — The Institutional Benchmark
The Bloomberg Terminal remains the reference point against which every other platform is measured. Its beta function lets users specify benchmark, period, frequency, and adjustment method explicitly, then displays the underlying regression with R-squared, standard error, and the full scatter of return observations. That transparency is what institutional users are actually paying for.
A single seat currently costs approximately $31,980 per year, dropping to around $28,320 per seat for firms running multiple terminals, typically under a two-year minimum contract. Add-ons such as the B-PIPE real-time data feed carry separate fees running into thousands per month.
Pros: unmatched breadth across more than 400 global exchanges, fully specifiable beta calculations, the messaging network that underpins large parts of OTC bond trading. Cons: the price excludes essentially every individual investor, contracts are rigid, and the platform has raised rates repeatedly.
Free Options Worth Knowing
Before paying for anything, two free routes cover a surprising amount of ground. Yahoo Finance publishes a five-year monthly beta on every quote page, which is adequate for a quick sanity check even though the methodology is fixed and undocumented in detail.
The second route is a spreadsheet. Download historical monthly closes for the stock and the benchmark, convert both to percentage returns, and apply SLOPE with the stock returns as the known-y values and the market returns as the known-x values. Add RSQ across the same ranges for R-squared, and the result is a fully documented beta whose every input is visible.
That manual approach costs nothing and remains the only way to be certain what was measured. Anyone comfortable running a coefficient of variation calculation already has the skills required.
How to Choose the Right Tool
Start with what the beta figure will be used for. If it feeds a discounted cash flow model or a cost of equity calculation, methodology control matters most — Wisesheets, Portfolio Visualizer, or a manual spreadsheet all deliver that. If the goal is screening a universe for defensive or aggressive names, Stock Rover or Koyfin will be faster.
Budget then narrows the field sharply. Under $15 per month, Wisesheets, Finbox, and Simply Wall St are the credible options. Between $30 and $80, Portfolio Visualizer, Stock Rover, Morningstar Investor, and Koyfin compete directly, and the choice usually comes down to whether portfolio analytics or security screening carries more weight. Above that, the products are built for advisors and institutions rather than individuals.
The third consideration is whether portfolio-level risk matters more than single-name risk. Portfolio beta is a weighted average of position betas, but weighted averages hide correlation effects that a factor regression exposes. Investors managing a genuinely diversified book should prioritise tools that measure at portfolio level, which is also where portfolio management software earns its cost.
Applying Beta Without Overtrusting It
Beta informs portfolio construction by letting investors dial aggregate market sensitivity up or down deliberately rather than by accident. Blending high-beta growth positions with low-beta defensive holdings produces a target portfolio beta, and that target should follow from risk tolerance rather than market forecasts.
In performance evaluation, beta is the denominator that separates skill from leverage. A manager returning 20 percent against a market that returned 15 percent has added nothing if the portfolio beta was 1.4. Risk-adjusted measures such as the Treynor ratio and Jensen’s alpha exist precisely to make that adjustment explicit.
Beta also drives cost of equity through the Capital Asset Pricing Model, which flows into discount rates and therefore into every valuation output. A 0.2 error in beta can move a terminal value materially, which is why practitioners often test a range of betas rather than a single point estimate. That same discipline applies to any financial forecasting exercise built on assumed inputs.
The limitations are equally important. Beta is backward-looking, ignores company-specific risk entirely, assumes a linear relationship that real markets violate during stress, and becomes unstable when R-squared is low. A stock with a beta of 1.2 and an R-squared of 0.15 has a beta figure that explains almost nothing about its actual behaviour.
Pro Tips for Working With Beta
- Always check R-squared alongside beta. Below roughly 0.30, the benchmark explains too little of the stock’s movement for beta to be reliable, and the number should carry a caveat wherever it is used.
- Fix your methodology and document it. Pick a window, frequency, and benchmark, then apply them consistently across every name being compared. Mixing methods produces comparisons that look rigorous but are not.
- Recalculate after capital structure changes. A debt raise, large buyback, or major acquisition changes levered beta immediately, while a five-year regression will take years to reflect it.
- Unlever before comparing across companies. Asset beta strips out financing effects and is the only fair basis for comparing operating risk between firms with different leverage.
- Test multiple windows. Running two-year, five-year, and ten-year betas on the same ticker reveals whether the relationship is stable or drifting, which a single figure hides completely.
- Pair beta with drawdown data. Beta describes average sensitivity; maximum drawdown describes what actually happened in the worst stretch. Both belong in the same risk review.
- Treat negative beta with scepticism. Genuine negative beta is rare outside inverse funds and certain commodities, and short-sample artefacts frequently produce it spuriously.
- Use free tools to validate paid ones. A manual spreadsheet regression is a cheap audit of any published figure, and disagreement is a signal to check the methodology rather than the arithmetic.
Frequently Asked Questions
What does a beta of 1.5 mean?
A beta of 1.5 indicates the asset has historically moved about 50 percent more than the benchmark in both directions. A 10 percent market gain would correspond to roughly a 15 percent gain in the asset, and a 10 percent decline to roughly a 15 percent loss. The relationship is historical and proportional, not a forecast.
Which tool gives the most accurate beta?
No provider is definitively more accurate, because beta is method-dependent rather than a single true value. Bloomberg and Portfolio Visualizer offer the most transparency about inputs, and a manual spreadsheet regression gives complete control. Accuracy in practice means knowing exactly what window, frequency, and benchmark produced the figure.
Can beta be calculated for free?
Yes. Yahoo Finance publishes beta on every quote page at no cost, Portfolio Visualizer’s free tier handles portfolios up to roughly fifteen assets, and Koyfin’s free plan includes two years of financials with advanced charting. A spreadsheet using SLOPE on historical return series costs nothing and offers the most control.
How often should beta be recalculated?
Quarterly review suits most holdings, with immediate recalculation after any material change to capital structure, business mix, or index membership. Stable large-cap positions can reasonably be reviewed annually. Rolling beta charts remove the question entirely by showing the trajectory continuously.
What is the difference between levered and unlevered beta?
Levered beta, also called equity beta, reflects both business risk and financial risk from debt in the capital structure. Unlevered beta, or asset beta, strips out the debt effect to isolate operating risk alone. Converting between the two requires the debt-to-equity ratio and the tax rate, and unlevered beta is the correct basis for cross-company comparison.
Is a high beta always bad?
No. High beta amplifies returns in rising markets and suits investors with long horizons and genuine tolerance for drawdowns. The risk is that the same amplification applies on the downside, so high-beta exposure needs to be a deliberate allocation decision rather than an unnoticed accumulation.
Does beta work for assets other than stocks?
Yes. Beta can be calculated for bonds, commodities, funds, and whole portfolios against any chosen benchmark. The mechanics are identical — covariance divided by benchmark variance — though benchmark selection becomes more consequential for assets whose returns are only loosely tied to equity indices.
Conclusion
Beta remains one of the most useful risk measures available precisely because it is simple, comparable across securities, and directly usable in valuation. Its weakness is that simplicity invites overtrust, and a figure pulled from a screen without knowing its inputs is closer to decoration than analysis.
The right tool depends on the job. Spreadsheet add-ons and free regressions give full methodological control at almost no cost. Mid-tier platforms trade some of that control for speed, coverage, and portfolio-level analytics. Institutional terminals sell transparency and breadth at a price only firms can justify.
Whichever platform ends up in the workflow, the discipline is the same: know the window, know the benchmark, check R-squared, and never let a single number stand in for a risk assessment. Beta is one input among several, and the investors who use it well are the ones who treat it that way. Building that habit alongside a broader investment portfolio framework is what turns a statistic into a decision.
